

找到约 115,000 条结果 (用时 0.65 秒)

Google 学术 : Existing therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

Metastatic colorectal cancer: ESMO Clinical Practice ... - Van Cutsem - 被引用次数 : 524

... in colorectal cancer patients treated with first-line ... - Scartozzi - 被引用次数 : 321

... -based chemotherapy as first-line treatment in patients ... - Soria - 被引用次数 : 227

Randomized Three Arm Phase III Trial on Induction Treatment With a ...

<https://ichgcp.net/clinical-trials-registry/NCT00973609> ▼ 翻译此页

Bevacizumab Alone vs. no Maintenance Treatment and Reinduction in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer ... colorectal cancer after first line induction treatment for 24 weeks with a ... strategy compared with a treatment until progression strategy for oxaliplatin-based

[PDF] TA212 Colorectal cancer (metastatic) - bevacizumab - NICE

<https://www.nice.org.uk/.../ta212-colorectal-cancer-metastatic-bevacizumab-...> ▼ 翻译此页

The search strategy from the original ERG report was re-run on the Cochrane ... fluoropyrimidine-based chemotherapy had a UK marketing authorisation that ... compared with chemotherapy alone in patients with metastatic colorectal cancer progressing after a first-line bevacizumab-containing treatment (Bennouna et al.

[PDF] pre-referral - NICE

<https://www.nice.org.uk/guidance/gid-ta10065/.../draft-scope-pre-referral> ▼ 翻译此页

Treatment of metastatic colorectal cancer may involve a combination of surgery ... has progressed following treatment with oxaliplatin and irinotecan based ...

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 42410

Manuscript Type: MINIREVIEWS

Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

Ozkan Kanat, Hulya Ertas

Abstract

Continuous inhibition of angiogenesis beyond progression is an emerging treatment concept in the management of metastatic colorectal cancer patients with prior bevacizumab exposure. Treatment options include the continuation or reintroduction of bevacizumab during the second-line chemotherapy or switching to a different

Match Overview

1	Internet 81 words crawled on 24-Nov-2017 link.springer.com	3%
2	Internet 72 words crawled on 08-Dec-2017 www.hematologyandoncology.net	2%
3	Internet 35 words crawled on 29-Jun-2018 ascopubs.org	1%
4	Internet 31 words crawled on 23-Dec-2017 cad1968.blogspot.com	1%
5	Internet 24 words crawled on 07-Nov-2018 www.medsci.org	1%
6	Internet 24 words crawled on 25-Apr-2016 www.ncbi.nlm.nih.gov	1%
7	Internet 24 words crawled on 24-Nov-2017 www.dovepress.com	1%
8	Crossref 22 words Michael T. Serzan, Benjamin A. Weinberg, Mohamed E. Salem. "Second Line Therapies for Metastatic Colorectal Cancer: A Review of the Literature"	1%
9	Crossref 20 words Giampieri, Riccardo, Marta Caporale, Filippo Di Cristofano, Filippo De Braud, Franco	1%
10	Internet 17 words crawled on 31-Aug-2017 www.esmo.org	1%
11	Crossref 16 words Arnold, Dirk, and Alexander Stein. "New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: A Review of the Literature"	1%

[全部](#)[新闻](#)[图片](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 117,000 条结果 (用时 0.52 秒)

Anti-angiogenic therapies for metastatic colorectal cancer: Current and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848143/> ▼ [翻译此页](#)

作者: I Marques - 2013 - 被引用次数: 31 - [相关文章](#)

The only potentially curative **treatment** for **patients** with liver **metastasis** is The combination chemotherapy is the only standard for **first-line treatment** of mCRC. ... mCRC: **Metastatic colorectal cancer**; PFS: **Progression-free-survival**; OS: by irinotecan-based chemotherapy + **bevacizumab**, followed by an **anti-EGFR** agent ...

Ramucirumab, another anti-angiogenic agent for metastatic colorectal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517427/> ▼ [翻译此页](#)

作者: G Goel - 2015 - 被引用次数: 9 - [相关文章](#)

2015年7月28日 - This has also resulted in further crowding of the **existing treatment** landscape, ... the efficacy of these VEGF inhibition **strategies** in the **treatment** of mCRC. ... in **patients** with **metastatic colorectal cancer**) was the first study to demonstrate ... that **progressed** during or **after first-line therapy** with **bevacizumab**, ...

[PDF]

New Directions in Anti-angiogenesis Therapy in Metastatic Colorectal ...

www.hkjr.org/system/files/v15n4S_46New.pdf ▼ [翻译此页](#)

作者: HH Loong - 被引用次数: 1 - [相关文章](#)

angiogenic targeted **therapies** in **metastatic colorectal cancer** and how they may affect the practice of ... **after first-line therapy**, the role of **bevacizumab** as.

[PDF]

Advancing Outcomes for the Treatment of Metastatic Colorectal Cancer

<https://angio.org/wp-content/uploads/2013/10/mCRC-White-Paper.pdf> ▼ [翻译此页](#)

A Report Based on a U.S. Expert Summit for **Metastatic** ... These **treatments** have led to a shift in

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 126,000 条结果 (用时 0.55 秒)

Anti-angiogenic therapies for metastatic colorectal cancer: Current and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848143/> ▾ [翻译此页](#)作者: I Marques - 2013 - 被引用次数: 31 - [相关文章](#)

The only potentially curative **treatment** for **patients** with liver **metastasis** is The combination chemotherapy is the only standard for **first-line treatment** of mCRC. ... mCRC: **Metastatic colorectal cancer**; PFS: **Progression-free-survival**; OS: by irinotecan-based chemotherapy + **bevacizumab**, followed by an **anti-EGFR** agent ...

Antiangiogenesis therapy in the treatment of metastatic colorectal cancer

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481559/> ▾ [翻译此页](#)作者: A Grothey - 2012 - 被引用次数: 24 - [相关文章](#)

Antiangiogenic therapies currently in development for **metastatic colorectal cancer**. **bevacizumab** to IFL in the **first-line** setting of mCRC, although **patients** with WT of **bevacizumab** into second-line **therapy** is delaying tumor **progression** rather ... and oxaliplatin- or irinotecan-based chemotherapy was discontinued **after** ...

[PDF]

New Directions in Anti-angiogenesis Therapy in Metastatic Colorectal ...

www.hkjr.org/system/files/v15n4S_46New.pdf ▾ [翻译此页](#)作者: HH Loong - 被引用次数: 1 - [相关文章](#)

angiogenic targeted **therapies** in **metastatic colorectal cancer** and how they may affect the practice of ... **after first-line therapy**, the role of **bevacizumab** as.

Toward optimized front-line therapeutic strategies in patients with ...

<https://academic.oup.com/annonc/article/21/8/1579/153931> - [翻译此页](#)作者: R Adam - 2010 - 被引用次数: 81 - [相关文章](#)

2010年3月10日 - **Metastatic colorectal cancer** is a particularly frequent and severe cancer. ... and leads to the risk of tumor **progression after** an initial response [25]; in ... To date, no biomarker demonstrated a predictive impact on **antiangiogenic treatment** ... outcome of **patients** treated with a **bevacizumab-based treatment**.

Ramucirumab, another anti-angiogenic agent for metastatic colorectal ...

<https://jhoonline.biomedcentral.com/articles/10.1186/s13045-015-0183-8> ▾ [翻译此页](#)作者: G Goel - 2015 - 被引用次数: 9 - [相关文章](#)

2015年7月28日 - This has also resulted in further crowding of the **existing treatment** landscape, ... the efficacy of these VEGF inhibition **strategies** in the **treatment** of mCRC. ... in **patients** with **metastatic**